Latest News and Press Releases

MicrobiotiX gains IND approval to initiate clinical trials for its pneumonia therapy designed to combat antibiotic-resistant superbugs.

Dewpoint Therapeutics today announced the opening of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for DPTX3186.

Lausanne, Switzerland — 1st October 2025 – HemostOD, a private Swiss company pioneering the ex vivo manufacturing of donor-free, off-the-shelf universal human blood platelets, today announced the...

NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...

FDA approves Longeveron's Investigational New Drug (IND) application for stem cell therapy as a potential treatment for pediatric dilated cardiomyopathy.

台灣, May 01, 2025 (GLOBE NEWSWIRE) -- 致力於癌症創新療法研發的台灣浩鼎生技 （4174.TWO） 今（5/1）日（美國時間4/30） 宣布，旗下新藥OBI-902已獲美國食品藥物管理局（FDA）核准臨床試驗申請（IND），將展開一期/二期臨床試驗。這項試驗預計招募晚期實體腫瘤患者。浩鼎視此次通過IND，為開發進程的重要里程碑，代表此一新世代Trop-2...

台湾, May 01, 2025 (GLOBE NEWSWIRE) -- 致力于癌症创新疗法研发的台湾浩鼎生技（4174.TWO）今（5/1）日（美国时间4/30）宣布，旗下新药OBI-902已获美国食品药物管理局（FDA）核准临床试验申请（IND），将展开一期/二期临床试验。这项试验预计招募晚期实体肿瘤患者。浩鼎视此次通过IND，为开发进程的重要里程碑，代表此一新世代Trop-2...

TAIPEI, Taiwan, May 01, 2025 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (“OBI”), a clinical stage oncology company（4174.TWO), today announced that the U.S. Food and Drug Administration (FDA） has cleared...

Minovia Therapeutics Announces FDA Clearance of Second IND Application, for a Phase II Clinical Trial of Lead Product MNV-201 in Pearson Syndrome

NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...